The pharmacodynamics and pharmacokinetics of cisatracurium in patients with renal or hepatic failure

Current Opinion in Anaesthesiology

Volumn 9, Issue SUPPL. 1, 1996, Pages

  Hunter, Jennifer M ^a,c   De Wolf, Andre ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATRACURIUM; NEUROMUSCULAR BLOCKING AGENT;

ADULT; AGED; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; DOSE TIME EFFECT RELATION; ELECTIVE SURGERY; FEMALE; HUMAN; KIDNEY FAILURE; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MULTICENTER STUDY; NEUROMUSCULAR BLOCKING; PRIORITY JOURNAL;

EID: 0029973457     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001503-199604001-00009     Document Type: Article

References (18)

1. Bevan DR, Bevan JC, Donati F: Muscle relaxants in clinical anaesthesia. Chicago: Year Book Medical Publishers; 1988.
2. Ward S, Boheimer N, Weatherley BC, Simmonds RJ, Dopson TA: Pharmacokinetics of atracurium and its metabolites in patients with normal renal function, and in patients with renal failure. Br J Anaesth 1987, 59:697-706.
3. Fahey MR, Rupp SM, Fisher DM, Miller RD, Sharma M, Canfell C, Castagnoli K, Hennis PJ: The pharmacokinetics and pharmacodynamics of atracurium in patients with and without renal failure. Anesthesiology 1984, 61:699-702.
4. DeBros FM, Lai A, Scott R, deBros J, Batson AG, Goudsouzian N, Ali HH, Cosimi AB, Savarese JJ: Pharmacokinetics and pharmacodynamics of atracurium during isoflurane anesthesia in normal and anephric patients. Anesth Analg 1986, 65:743-746.
5. Vandenbrom RHG, Weirda JMKH, Agoston S: Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. Clin Pharmacokinet 1990, 19:230-240.
6. Cook DR, Brandom BW, Stiller RL, Woelfel S, Lai A, Slater J: Pharmacokinetics of atracurium in normal and liver failure patients [abstract]. Anesthesiology 1984, 61:A433.
7. Parker CJR, Hunter JM: Pharmacokinetics of atracurium and laudanosine in patients with hepatic cirrhosis. Br J Anaesth 1989, 62:177-183.
8. Bell CF, Hunter JM, Jones RS, Utting JE: Use of atracurium and vecuronium in patients with oesophageal varices. Br J Anaesth 1985, 57:160-168.
9. Belmont MR, Lien CA, Quessy S, Abou-Donia MM, Abalos A, Eppich L, Savarese JJ: The clinical neuromuscular pharmacology of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology 1995, 82:1139-1145.
10. Lepage JY, Malinovsky JM, Malinge M, Cozian A, Pinaud M: Comparison of equipotent doses of 51W89 and atracurium [abstract]. Anesthesiology 1994, 81:A1090.
11. Lien CA, Belmont MR, Abalos A, Eppich L, Quessy S, Abou-Donia MM, Savarese JJ: The cardiovascular effects and histamine-releasing properties of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology 1995, 82:1131-1138.
12. Welch R, Brown A, Ravitch J, Dahl R: The in vivo degradation of cisatracurium, the R-cis,R′-cis isomer of atracurium, in human and rat plasma. Clin Pharmacol Ther 1995, 58:132-142.
13. Boyd AH, Eastwood NB, Parker CJR, Hunter JM: Pharmacodynamics of the 1R-cis,1′R-cis isomer of atracurium (51W89) in health and chronic renal failure. Br J Anaesth 1995, 74:400-404.
14. Eastwood NB, Boyd AH, Parker CJR, Hunter JM: Pharmacokinetics of 1R-cis,1′R-cis atracurium besylate (51W89) and plasma laudanosine concentrations in health and chronic renal failure. Br J Anaesth 1995, 75:431-435.
15. Tullock W, Scott V, Smith DA, Phillips L, Cooke DR: Kinetics/dynamics of 51W89 in liver transplant patients and in healthy patients [abstract]. Anesthesiology 1994, 81:A1076.
16. Nakashima E, Benet LZ: General treatment of mean residence time, clearance and volume parameters in linear mammillary models with elimination from any compartment. J Pharmacokinet Biopharmacol 1988, 16:475-492.
17. Parker CJR, Jones JE, Hunter JM: Disposition of infusions of atracurium and its metabolite, laudanosine, in patients in renal and respiratory failure in an ITU. Br J Anaesth 1988, 61:531-540.
18. Bion JF, Bowden MI, Chow B, Honisberger L, Weatherley BC: Atracurium infusions in patients with fulminant hepatic failure awaiting liver transplantation. Intensive Care Med 1993, 19 (suppl 2):S94-S98.